ImmunityBio (IBRX): The BCG Bottleneck Nobody Modeled
Investors are focused on efficacy and dilution. The more interesting question is whether ImmunityBio is quietly controlling the scarce input behind its own growth curve.
点赞
收藏
点踩
分享评论
?
参与讨论
Investors are focused on efficacy and dilution. The more interesting question is whether ImmunityBio is quietly controlling the scarce input behind its own growth curve.